Emergent Biosolutions’ (EBS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Emergent Biosolutions (NYSE:EBS) in a research note released on Tuesday,Benzinga reports. The brokerage currently has a $15.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Weiss Ratings restated a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 8th. Zacks Research raised Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. Finally, Wall Street Zen raised shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 30th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Emergent Biosolutions presently has an average rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Stock Up 0.7%

Shares of NYSE EBS opened at $12.29 on Tuesday. The stock has a market cap of $645.47 million, a P/E ratio of 9.45 and a beta of 2.32. The firm has a 50 day moving average price of $10.61 and a 200 day moving average price of $8.65. The company has a debt-to-equity ratio of 1.14, a quick ratio of 3.15 and a current ratio of 5.76. Emergent Biosolutions has a 52-week low of $4.02 and a 52-week high of $13.41.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter. Emergent Biosolutions had a return on equity of 20.85% and a net margin of 9.62%.The firm had revenue of $222.50 million for the quarter. Analysts expect that Emergent Biosolutions will post -0.63 EPS for the current year.

Insider Buying and Selling

In other news, EVP Coleen Glessner sold 30,608 shares of the business’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $10.00, for a total value of $306,080.00. Following the sale, the executive vice president owned 144,319 shares of the company’s stock, valued at $1,443,190. The trade was a 17.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronald Richard sold 21,984 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $11.97, for a total transaction of $263,148.48. Following the completion of the transaction, the director directly owned 98,417 shares of the company’s stock, valued at approximately $1,178,051.49. This trade represents a 18.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Emergent Biosolutions

A number of institutional investors and hedge funds have recently modified their holdings of EBS. Sherbrooke Park Advisers LLC bought a new position in Emergent Biosolutions during the third quarter worth about $192,000. Morse Asset Management Inc boosted its stake in shares of Emergent Biosolutions by 4.7% during the 3rd quarter. Morse Asset Management Inc now owns 217,925 shares of the biopharmaceutical company’s stock worth $1,922,000 after acquiring an additional 9,881 shares during the period. Jain Global LLC acquired a new position in shares of Emergent Biosolutions during the 3rd quarter worth approximately $4,487,000. Creative Planning raised its stake in Emergent Biosolutions by 44.7% in the 3rd quarter. Creative Planning now owns 21,742 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 6,718 shares during the period. Finally, Squarepoint Ops LLC raised its stake in Emergent Biosolutions by 607.0% in the 3rd quarter. Squarepoint Ops LLC now owns 172,797 shares of the biopharmaceutical company’s stock valued at $1,524,000 after acquiring an additional 148,357 shares during the period. 78.40% of the stock is owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.